MEP Schenk: Europe treats pharma as a cost, not a catalyst

EU PERSPECTIVES - Europe has the science, the workforce, and the global footprint to lead in pharmaceutical innovation. However, it still treats the pharmaceutical sector as a budget line, not a strategic asset. Read more

MEP Oliver Schenk (EPP, pictured left) discussing pharma industry topics. Photo: Bayer